FindMyKOL
Clinical trialNCT01573052CompletedPhase 4Interventional

Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal

NCT01573052 is a phase 4 interventional trial sponsored by VA Salt Lake City Health Care System. As of 21 Nov 2026, it is completed. It studies Chlordiazepoxide and Gabapentin in Alcohol Withdrawal. The registry lists an enrollment of 26 participants at 1 site in 1 country. The registry lists a start date of 31 Mar 2004 and a primary completion date of 31 Aug 2010.

SponsorVA Salt Lake City Health Care SystemEnrollment26Alcohol Withdrawal
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01573052
FieldValue
Registry IDNCT01573052
StatusCompleted
PhasePhase 4
Study typeInterventional trial
Lead sponsorVA Salt Lake City Health Care System
Enrollment26
Registered sites1
Countries1
ConditionsAlcohol Withdrawal
DrugsChlordiazepoxide and Gabapentin
Start31 Mar 2004
Primary completion31 Aug 2010
Study completion30 Sept 2010
Last update posted17 Aug 2020

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A randomized, double-blind controlled trial comparing treatment outcomes between chlordiazepoxide, or gabapentin to treat alcohol withdrawal syndrome in alcohol dependent veteran subjects. The objective of this trial is to compare the safety and effectiveness of these two medications. Intervention is a fixed dose taper of chlordiazepoxide, or gabapentin over 6 days. Subjects will be evaluated for 7-10 days to monitor alcohol abstinence, withdrawal severity scores, adverse events including ataxia, sedation, cognitive function and alcohol craving.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Utah, United States1 site
  • George E Wahlen Va Medical Center

    Salt Lake City

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtah: 1 siteUT1ColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT01573052

Each answer restates registry values shown on this page.

What is NCT01573052?

NCT01573052 is a phase 4 interventional trial sponsored by VA Salt Lake City Health Care System. It studies Chlordiazepoxide and Gabapentin in Alcohol Withdrawal.

Who leads NCT01573052?

The registry names Christopher J Stock, PharmD (principal investigator, Salt Lake VA Health Care System) as the overall official.

Where does NCT01573052 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT01573052 study?

The registered drug and biological interventions are Chlordiazepoxide and Gabapentin.

When did NCT01573052 end?

The registry lists a primary completion date of 31 Aug 2010 and a study completion date of 30 Sept 2010. The sponsor last updated the record on 17 Aug 2020.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.